Charles River Labs Extends CEO's Employment and Elects New Board Members

Details

extended the employment term of its Chair, President, and CEO, James C. Foster, by an additional year, until February 12, 2027. The company also held its Annual Meeting of Shareholders where seven directors were re-elected, and four new directors were appointed to fill vacancies. Shareholders approved the compensation of named executive officers and ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal 2024. However, they did not approve a PETA proposal to publish a report on non-human primates imported by the company.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.